Somatropin Market Synopsis:<\/p>\n
Somatropin Market Size Was Valued at USD 4.25 Billion in 2023, and is Projected to Reach USD 7.94 Billion by 2032, Growing at a CAGR of 7.19% From 2024-2032.<\/p>\n
Somatropin is recombinant human growth hormone (rhGH) that is applied for a number of pathologies, which are associated with growth failure. It fosters growth and it is used to treat hormonal deficiencies, Turner syndrome, and chronic kidney disease among other diseases. This agent is commonly given through injections in order to help develop tissues and bones. <\/p>\n
Somatropin market has expanded all over the world due to its usage in treating patients with this hormone deficiency and other disorders affecting physical development. SOMATROPIN is one of the most frequently used recombinant hormones in clinical practice and is a synthetic growth hormone similar to that produced by the human pituitary gland. Although synthetic somatropin is used frequently than recombinant, Synthetic somatropin provides a cheaper solution to the problem in certain parts of the world.<\/p>\n
Emerging diseases such as growth hormone deficiency, chronic kidney disease, idiopathic short stature will fuel the growth of the somatropin market. Besides, the emergence of new indications for somatropin incline Prader-Willi syndrome and Turner syndrome have broadened the supply side of this market. Publicity in refinement of recombinant somatropin and consistent endeavors to understand its therapeutic applications are the factors which are helping the market mature on the other hand. There exist advanced pharmaceutical formations and methods of drug administration which have been aimed at enhancing the quality of the results and administering the drugs easily.<\/p>\n
As a result of widespread health consciousness across the world, crowding of healthcare products, especially for children and adolescents, whose physical stature is stunted, this product would be trendy in the marketplace. In addition, increased availability of new biosimilars is increasing affordability and cost- effectiveness of somatropin therapies and hence increasing their utilization. The demand for somatropin is also appraised in developed countries having good healthcare infrastructure, along with improved reimbursement policies in North America, European Union, and Asia-Pacific.<\/p>\n
Somatropin Market Trend Analysis:<\/p>\n
Growth in Biosimilars<\/p>\n
The increase in biosimilars within the somatropin market allows for the formation of additional pricier but cost-effective forms of therapeutic recombinant human growth hormone compared to the initial innovation of first-generation r-hGH products on the market. Subsequently, biosimilars, which are products that are been formulated to be similar to an FDA-approved reference product, has received a fair deal of attention in different markets across the global especially the European and the North American markets. As healthcare systems strive to decrease their costs while upholding efficiency biosimilars help offset the cost of treatment.<\/p>\n
It is predicted that high competition from biosimilars to somatropin will also establish a market competition thus lowering prices to avail appropriate treatments to patients. Therefore, there is improved access to cheaper medicines that help all healthcare providers treat individuals with growth hormone deficiency and all sorts of associated conditions. It is expected that this trend will enhance market development particularly the emerging markets where cost of health care is still a big issue of concern. As biosimilar development extends and regulatory clearances are accorded in the future, this part of the somatropin market should increase further.<\/p>\n
Expanding in Emerging Markets<\/p>\n
The somatropin market is benefited significantly from emerging markets due to better health care facility and better health care spending. Many developing nations in Asia-Pacific, Latin America, and some regions of the Middle East and Africa are getting better in terms of medical infrastructure and a fairly wealthy population than willing to spend on health. These regions will experience advancements in medical treatments\u2019 availability so there will be increased demand of somatropin in the management of growth disorders.<\/p>\n
There is growing emphasis on developing outreach for the utilization of health care services in such places. As the number of customers diagnosed with growth hormone deficiency and other conditions responsive to somatropin increases, there will be an increase in demand on the market. To a certain extent, the growth in the emerging markets could be attributed in the near-term to players that better manage the regulatory challenges, and those that are able to form strategic alliances with the local health care departments.<\/p>\n
Somatropin Market Segment Analysis:<\/p>\n
Somatropin Market is Segmented on the basis of Type, Application, Distribution Channel, End User, and Region.<\/p>\n
By Product Type, Recombinant Somatropin segment is expected to dominate the market during the forecast period<\/p>\n
Recombinant Somatropin of all the kinds of growth hormone that is administered to patients, recombinant somatropin is perhaps the most common. It is synthesized by the recombinant DNA technique and has the same molecular form of the biosynthetic growth hormone. This product type has stated growing particularly due to the disease severity attenuation by the product illustrated in the treatment of growth hormone deficiency and other related ailments.<\/p>\n
Synthetic Somatropin Human somatropin is produced both in recombinant and synthetic formulations and the latter is cheaper but not as popular as the former. It is more commonly synthesized chemically than being made from recombinant DNA technology as may be expected. It is less effective than recombinant somatropin however, its application is limited because customers tend to buy recombinant somatropin as a purer alternative. The recombinant somatropin segment, in particular the segment related to GHN\u2019s DNA expression system, is currently leading due to the higher efficiency and versatility of the product. The customer pressure for defining more affordable therapies, particularly throughout the developing countries, contributes to the expanded demand for synthetic somatropin. Nevertheless, the general inclination is in the direction of recombinant somatropin attributing to superior effective and more favorable patient choice.<\/p>\n
By Application, Growth Hormone Deficiency segment expected to held the largest share <\/p>\n
Growth Hormone Deficiency One of the most frequent uses of somatropin is in the treatment of any patient who has a deficiency in the body\u2019s natural creation of growth hormone which results in slow growth. Turner Syndrome: Somatropin is urged to cure girls with Turner syndrome that is a chromosomal abnormality that affects height and other complications. Chronic Kidney Disease The children with chronic kidney disease are poorly grown, and somatropin is employed to facilitate the onset of some growth. Idiopathic Short Stature Somatropin is also used when no other cause of stunted growth is found and for idiopathic short stature to help the child grow taller.<\/p>\n
Prader-Willi Syndrome Somatropin is prescribed to children with Prader-Willi syndrome which is a hereditary disorder and the main features of which are short height and learning difficulties. All of these applications are a major part of the somatropin market, though the largest application area is growth hormone deficiency. The markets for somatropin treatments in these regions will remain on the rise as awareness regarding the disease and its diagnosis grows.<\/p>\n
Somatropin Market Regional Insights: <\/p>\n
North America is Expected to Dominate the Market Over the Forecast period <\/p>\n
The demand for somatropin is high in North America due to the better exposure of health care systems, high spending on health care, and better diagnostic structures. America alone is the largest consumer of somatropin mainly because of increased incidence of growth hormone deficiency and other related disorders. Furthermore, the augmentations in the demand of somatropin therapy across the globe make it possible for the region to afford the availability of both the branded and biosimilar products.<\/p>\n
North America also holds a larger share in somatropin market because of availability of favourable regulatory environment adorned to the safety and effectiveness of these therapies. In addition, subsequent research and development work of large number of pharmaceutical firms located in this region has modified the somatropin product line as well as the modes of administration. The major factors restraining the growth of the somatropin market area Higher degree of patient awareness and a wider choice of treatments would allow North America to continue leading the somatropin market.<\/p>\n
Active Key Players in the Somatropin Market <\/p>\n
Anke Bio (China)<\/p>\n
Biopartners (Switzerland)<\/p>\n
Eli Lilly and Company (United States)<\/p>\n
Genentech (United States)<\/p>\n
Hugel, Inc. (South Korea)<\/p>\n
LG Life Sciences (South Korea)<\/p>\n
Merck & Co., Inc. (United States)<\/p>\n
Novo Nordisk (Denmark)<\/p>\n
Pfizer Inc. (United States)<\/p>\n
Sandoz (Novartis) (Switzerland)<\/p>\n
Stada Arzneimittel AG (Germany)<\/p>\n
Teva Pharmaceutical Industries Ltd. (Israel)<\/p>\n
Other Active Players.<\/p>\n
Key Industry Developments in the Somatropin Market:<\/p>\n
In April 2023, Novo Nordisk A\/S, a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for both children and adults. The FDA approval of the new indication for children with GHD is based on data from the phase 3 REAL4 study.<\/p>\n","protected":false},"excerpt":{"rendered":"
Somatropin is recombinant human growth hormone (rhGH) that is applied for a number of pathologies, which are associated with growth failure.<\/p>\n","protected":false},"featured_media":5118,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-8978","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n